NASDAQ:LENZ LENZ Therapeutics Q2 2025 Earnings Report $3.58 -0.21 (-5.54%) Closing price 04:00 PM EasternExtended Trading$3.66 +0.09 (+2.37%) As of 04:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast LENZ Therapeutics EPS ResultsActual EPS-$0.53Consensus EPS -$0.58Beat/MissBeat by +$0.05One Year Ago EPSN/ALENZ Therapeutics Revenue ResultsActual Revenue$5.00 millionExpected Revenue$5.00 millionBeat/MissMet ExpectationsYoY Revenue GrowthN/ALENZ Therapeutics Announcement DetailsQuarterQ2 2025Date7/30/2025TimeBefore Market OpensConference Call DateWednesday, July 30, 2025Conference Call Time8:00AM ETUpcoming EarningsLENZ Therapeutics' Q3 2026 earnings is estimated for Wednesday, November 4, 2026, based on past reporting schedules, with a conference call scheduled at 8:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) LENZ Therapeutics Earnings HeadlinesINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZOctober 1 at 10:00 AM | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZSeptember 29 at 5:19 PM | globenewswire.comTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.October 2 at 1:00 AM | Porter & Company (Ad)LENZ Therapeutics: Below Cash For A ReasonSeptember 25, 2026 | seekingalpha.comLENZ Therapeutics, Inc. (LENZ) Stock Price, News, Quote & History - Yahoo FinanceSeptember 25, 2026 | finance.yahoo.comLENZ Therapeutics (LENZ)September 24, 2026 | es.investing.comSee More LENZ Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like LENZ Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on LENZ Therapeutics and other key companies, straight to your email. Email Address About LENZ TherapeuticsLENZ Therapeutics (NASDAQ:LENZ) is a biopharmaceutical company focused on developing and commercializing ophthalmic medicines for people with presbyopia, an age-related condition that reduces the eye’s ability to focus on near objects. The company’s lead product is VIZZ (aceclidine hydrochloride ophthalmic solution), a prescription eye drop designed to improve near vision by creating a pinhole effect through pupil modulation while aiming to preserve distance vision. In July 2025, the U.S. Food and Drug Administration approved VIZZ for the treatment of presbyopia in adults. The approval marked the company’s transition from a clinical-stage developer to a commercial ophthalmology company. LENZ is focused on making VIZZ available to patients and eye-care professionals in the United States and may pursue additional regulatory and commercial opportunities in other geographies. LENZ Therapeutics was established to address unmet needs in the treatment of presbyopia and is headquartered in San Diego, California. The company is led by Chief Executive Officer Eef Schimmelpennink, who has experience in the pharmaceutical and ophthalmology industries. Its shares trade on the Nasdaq under the symbol LENZ.View LENZ Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Time to Nibble on MCD Stock After it Enters Oversold Territory?McCormick Stock Trades Cheap, Offers Dividend Growth and Unilever Deal UpsideMicron’s Earnings Reveal Why the AI Memory Boom May Last LongerAnthropic's IPO Could Put Amazon's and Alphabet's Paper Profits to the TestBoeing’s Fighter Victory Opens the Door to Decades of Defense RevenueCorning and AT&T's $3 Billion Fiber Deal Reveals Where AI Spending Goes NextTarget's Holiday Blitz: Slashing Prices to Capture Market Share Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
